CNTB — Connect Biopharma Holdings Limited

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for CNTB in the TickerWise workspace.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: CN
• Exchange: NASDAQ
• Employees: 62
• Website: https://www.connectbiopharm.com

Latest SEC filings for CNTB

• 2026-10-06SCHEDULE 13G
• 2026-09-308-K
• 2026-09-158-K
• 2026-08-15SCHEDULE 13G/A
• 2026-08-1210-Q
• 2026-08-128-K
• 2026-06-02EFFECT
• 2026-05-15F-3
• 2026-05-128-K
• 2026-05-1210-Q

Latest CNTB news

• 2026-10-19Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher Read article
• 2026-10-05Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast Read article
• 2026-10-04Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures Read article
• 2026-09-30Connect Biopharma stock jumps on positive COPD trial data
• 2026-09-30Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy Read article
• 2026-09-30Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript Read article
• 2026-09-30Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today?
• 2026-09-30CNTB Stock Whipsaws As Traders Weigh Mixed Trial Data And Analyst Cuts

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.